Vitalgen
Shanghai Vitalgen BioPharma Co., Ltd. (Vitalgen), founded in March 2020 and headquartered in Shanghai, China, translates cutting-edge gene delivery and gene editing techniques into clinically effective treatments for patients with unmet medical needs. Vitalgen operates a GMP-compliant commercial production platform built on its proprietary ViCas CRISPR/Cas editing tools, ViLNP lipid nanoparticles, and ViVec AAV capsids, developing gene therapies for hereditary diseases and neurodegenerative disorders across a pipeline that includes Bietti Crystalline Dystrophy (VGR-R01), AADC Deficiency, Parkinson's Disease, Gaucher Disease, and Glutaric Acidemia Type I. Several candidates have entered clinical trials and secured U.S. FDA Orphan Drug Designations and an EMA PRIME designation. Surfaced as a portfolio company of IDG Capital and added to the API Evangelist network. The company publishes a corporate marketing website only and exposes no public API, developer portal, or machine-readable surface.
Vitalgen is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Gene Therapy, Gene Editing, and Biopharmaceutical.
Vitalgen’s developer surface includes engineering blog and 1 more developer resources.
Kin Score
Resources
Company 2
The organization behind the API